CareLit Fachartikel

Treatment of previously untreated patients with chronic HCV genotype 1 infection with Boceprevir (BOC) in German real-life: High efficacy in patients with early virologic response

P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthoeft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2014 · Heft 08

Dokument
1144147
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthoeft, A Herrmann, M Hoesl, U Naumann, T Dahhan, D Hartmann, B Dreher, M Bilzer
Ausgabe
Heft 08 / 2014
Seiten
–
Erschienen: 2014-08-11 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0034-1386298

Zusammenfassung

Background: The achievement of early virologic response (EVR) during triple therapy of chronic HCV genotype 1 infection with boceprevir (BOC) was identified as predictor of high SVR rates of up to 90% and as predictor to shorten treatment to 24 weeks. This interim analysis of the NOVUS observational study aimed to investigate EVR during BOC triple therapy in German real-life and to identify factors associated with EVR. Methods: From April 2012 until January 2014, 536 patients with G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Patients were treated with pegylated…

Schlagworte

Lead Observational Study Germany After Zeitschrift für Gastroenterologie